Financial Performance
5Y price score: 497
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 403.3%
US$ Per
Share
By default your notes are visible only to you.
673.3
52-week range
999.0
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
5.5 %
Dividend Yield TTM
0.4 %
Market cap $
$ 105,966
Price / Earnings TTM
24.2
Price / Book TTM
(25.3)
PEG TTM
(1.4)
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
33.7 %
357.2 %
403.3 %
Free cash flow per share growth
68.4 %
79.5 %
239.1 %
Earnings per share growth
(17.6) %
242 %
295.7 %
Founded: 1,833
Employees: 44,000
Business Summary:
Latest Earnings Call Takeaways
2027 Q1 (Aug 5, 2026)
1) Strong Financial Performance - Revenues increased 8% to $105 billion; adjusted earnings per diluted share rose 20% to $9.93. - Three reporting segments achieved double-digit operating profit growth, indicating robust core business performance. - Adjusted earnings per diluted share guidance for the full year raised to $44.20 - $45, up from $43.80 - $44.60.
2) Strategic Initiatives and Leadership Transition - Kenny K. Cheung appointed as new CFO, emphasizing a focus on disciplined execution and capital allocation. - McKesson hosted an AI training event to empower teams in leveraging technology for operational improvements. - Continued investment in oncology and multispecialty platforms, with a focus on expanding community-based care and enhancing service offerings.
3) Segment Highlights - North American Pharmaceuticals: Revenues grew 5% to $86.8 billion, driven by higher prescription volumes, despite lower branded pharmaceutical pricing. - Oncology and Multispecialty: Revenues surged 33% to $14.2 billion, with strong organic growth and contributions from acquisitions. - Prescription Technology Solutions: Revenues increased 9% to $1.6 billion, supported by higher demand for access solutions.
4) Operational Investments and Future Outlook - Investment in a new regional distribution center in Oklahoma to enhance distribution capabilities. - Anticipated revenue growth of 5% to 9% and operating profit growth of 9% to 13% for fiscal 27. - Continued focus on AI and technology to improve operational efficiency and customer service.
5) Potential Headwinds and Market Dynamics - Ongoing market dynamics include lower branded pharmaceutical pricing and the impact of generic conversions. - The company is closely monitoring policy changes, particularly regarding the 340B program and IRA Part B, which could affect future operations. - The transcript lacks specific details on competitive pressures and market share changes, which could provide further insights into future performance.
Bottom line: McKesson's strong Q1 results and strategic initiatives position the company well for sustained growth, with a confident outlook for the remainder of fiscal 27, despite potential market headwinds. Shareholders can expect continued value creation through disciplined execution and strategic investments.
Annual Reports, Presentations And IR Contacts
Go to the websiteMcKesson Corporation — Financial Overview, Stock Price, Market Cap
McKesson Corporation is a company. Founded in 1833. As of August 26, 2026, the company's market capitalization is $105966127020 with a current stock price of $905.09.